JP2017531028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531028A5 JP2017531028A5 JP2017526774A JP2017526774A JP2017531028A5 JP 2017531028 A5 JP2017531028 A5 JP 2017531028A5 JP 2017526774 A JP2017526774 A JP 2017526774A JP 2017526774 A JP2017526774 A JP 2017526774A JP 2017531028 A5 JP2017531028 A5 JP 2017531028A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- cdrs
- cancer
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims description 65
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 56
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 17
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 17
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 8
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 8
- 241000282465 Canis Species 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 7
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 6
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 2
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940043267 rhodamine b Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- QOFZZTBWWJNFCA-UHFFFAOYSA-N texas red-X Chemical compound [O-]S(=O)(=O)C1=CC(S(=O)(=O)NCCCCCC(=O)O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 QOFZZTBWWJNFCA-UHFFFAOYSA-N 0.000 description 2
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 1
- BUJRUSRXHJKUQE-UHFFFAOYSA-N 5-carboxy-X-rhodamine triethylammonium salt Chemical compound CC[NH+](CC)CC.[O-]C(=O)C1=CC(C(=O)[O-])=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 BUJRUSRXHJKUQE-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012104 Alexa Fluor 500 Substances 0.000 description 1
- 239000012105 Alexa Fluor 514 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 239000012115 Alexa Fluor 660 Substances 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 239000012118 Alexa Fluor 750 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940122544 PD-1 agonist Drugs 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- APJYDQYYACXCRM-UHFFFAOYSA-N Tryptamine Natural products C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 1
- APERIXFHHNDFQV-UHFFFAOYSA-N [2-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]-4-[3,6-bis(dimethylamino)xanthen-9-ylidene]cyclohexa-2,5-dien-1-ylidene]-bis(carboxymethyl)azanium;chloride Chemical compound [Cl-].C12=CC=C(N(C)C)C=C2OC2=CC(N(C)C)=CC=C2C1=C(C=1)C=CC(=[N+](CC(O)=O)CC(O)=O)C=1OCCOC1=CC(C)=CC=C1N(CC(O)=O)CC(O)=O APERIXFHHNDFQV-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- -1 hydroxy Tryptamine Chemical compound 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- MYIOYATURDILJN-UHFFFAOYSA-N rhodamine 110 Chemical compound [Cl-].C=12C=CC(N)=CC2=[O+]C2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O MYIOYATURDILJN-UHFFFAOYSA-N 0.000 description 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
- YEOUFHBJWTZWCZ-UHFFFAOYSA-M sulforhodamine G Chemical compound [Na+].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O YEOUFHBJWTZWCZ-UHFFFAOYSA-M 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033177P | 2014-08-05 | 2014-08-05 | |
| US62/033,177 | 2014-08-05 | ||
| US201462053366P | 2014-09-22 | 2014-09-22 | |
| US62/053,366 | 2014-09-22 | ||
| US201462093368P | 2014-12-17 | 2014-12-17 | |
| US62/093,368 | 2014-12-17 | ||
| PCT/IB2015/055943 WO2016020856A2 (en) | 2014-08-05 | 2015-08-05 | Immunological reagents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531028A JP2017531028A (ja) | 2017-10-19 |
| JP2017531028A5 true JP2017531028A5 (enExample) | 2018-09-20 |
| JP6629321B2 JP6629321B2 (ja) | 2020-01-15 |
Family
ID=53836144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526774A Active JP6629321B2 (ja) | 2014-08-05 | 2015-08-05 | 免疫学的試薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9982053B2 (enExample) |
| EP (1) | EP3177644B1 (enExample) |
| JP (1) | JP6629321B2 (enExample) |
| KR (1) | KR102357893B1 (enExample) |
| CN (1) | CN107074947B (enExample) |
| AU (1) | AU2015298356B2 (enExample) |
| CA (1) | CA2957258C (enExample) |
| DK (1) | DK3177644T3 (enExample) |
| ES (1) | ES2847311T3 (enExample) |
| PL (1) | PL3177644T3 (enExample) |
| PT (1) | PT3177644T (enExample) |
| SG (1) | SG11201700672YA (enExample) |
| WO (1) | WO2016020856A2 (enExample) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| CN105339389B (zh) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| EP3177644B1 (en) * | 2014-08-05 | 2020-10-07 | Mabquest SA | Immunological reagents binding to pd-1 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| BR112017011092A2 (pt) | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| CN108368170B (zh) | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| EA201890790A1 (ru) | 2015-09-29 | 2018-10-31 | Селджин Корпорейшн | Связывающие pd-1 белки и способы их применения |
| HUE057837T2 (hu) | 2015-11-03 | 2022-06-28 | Janssen Biotech Inc | PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik |
| CR20180318A (es) | 2015-12-14 | 2018-09-19 | Macrogenics Inc | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| EP3405497A2 (en) | 2016-01-22 | 2018-11-28 | Mabquest SA | Immunological reagents |
| CN106008714B (zh) * | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
| MY195089A (en) | 2016-05-27 | 2023-01-10 | Agenus Inc | Anti-Tim-3 Antibodies and Methods of use thereof |
| EP3468586B1 (en) * | 2016-06-14 | 2024-08-07 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| JP2019531284A (ja) | 2016-09-19 | 2019-10-31 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法 |
| WO2018053401A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating vitiligo using pd-1 binding proteins |
| IL265800B2 (en) | 2016-10-11 | 2023-10-01 | Agenus Inc | Anti-LAG-3 antibodies and methods of using them |
| WO2018085468A1 (en) | 2016-11-01 | 2018-05-11 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| JP7086066B2 (ja) * | 2016-11-02 | 2022-06-17 | ジョンス セラピューティクス， インコーポレイテッド | Ｐｄ－１に対する抗体及びその使用 |
| WO2018106864A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
| PT3551660T (pt) | 2016-12-07 | 2023-11-30 | Ludwig Inst For Cancer Res Ltd | Anticorpos anti-ctla-4 e métodos de uso dos mesmos |
| EP3565841A1 (en) * | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| FI3565844T3 (fi) | 2017-01-09 | 2023-05-09 | Tesaro Inc | Menetelmiä syövän hoitamiseksi anti-pd-1 -vasta-aineilla |
| AU2018207172B2 (en) | 2017-01-13 | 2023-10-12 | Mink Therapeutics, Inc. | T cell receptors that bind to NY-ESO-1 and methods of use thereof |
| CN107474135B (zh) * | 2017-02-17 | 2020-08-18 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用 |
| WO2018162944A1 (en) | 2017-03-04 | 2018-09-13 | Shenzhen Runshin Bioscience | Recombinant antibodies to programmed death 1 (pd-1) and uses therefor |
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| KR20240017409A (ko) | 2017-04-13 | 2024-02-07 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| CN106939049B (zh) * | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| TWI805582B (zh) | 2017-05-01 | 2023-06-21 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體類和使用彼等之方法 |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| AU2018282094B2 (en) | 2017-06-05 | 2024-06-27 | Janssen Biotech, Inc. | Antibodies that specifically bind PD-1 and methods of use |
| KR20200052327A (ko) | 2017-09-04 | 2020-05-14 | 아게누스 인코포레이티드 | 혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법 |
| US11021540B2 (en) | 2017-09-07 | 2021-06-01 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
| WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| KR20200080304A (ko) | 2017-11-13 | 2020-07-06 | 크레센도 바이오로직스 리미티드 | Cd137에 결합하는 단일 도메인 항체 |
| CN108218988B (zh) * | 2017-11-29 | 2019-10-11 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| AR114127A1 (es) * | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| JP7430924B2 (ja) * | 2018-03-22 | 2024-02-14 | ケイレス アーゲー | 拮抗的抗原結合タンパク質 |
| CN112218883A (zh) | 2018-04-26 | 2021-01-12 | 艾吉纳斯公司 | 热休克蛋白结合肽组合物及其使用方法 |
| CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| EP4349411A3 (en) | 2018-06-20 | 2024-06-19 | Incyte Corporation | Anti-pd-1 antibodies and uses thereof |
| JP2022517324A (ja) | 2019-01-03 | 2022-03-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 癌を患っている被験者における、ｃｄ８陽性ｔ細胞依存性免疫応答を増強させるための方法及び医薬組成物 |
| US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| US12344850B2 (en) | 2019-07-30 | 2025-07-01 | Pairwise Plants Services, Inc. | Morphogenic regulators and methods of using the same |
| US11629190B2 (en) | 2019-08-15 | 2023-04-18 | Oregon State University | Canine antibody therapeutic for treating cancer |
| KR102231974B1 (ko) * | 2019-08-23 | 2021-03-25 | 한국과학기술원 | 사람의 프로그램된 세포사멸 단백질(pd-1)에 선택적으로 결합하는 신규한 폴리펩티드 및 이의 용도 |
| PE20221151A1 (es) | 2019-08-30 | 2022-07-18 | Agenus Inc | Anticuerpos anti-cd96 y sus metodos de uso |
| US12331330B2 (en) | 2019-10-23 | 2025-06-17 | Pairwise Plants Services, Inc. | Compositions and methods for RNA-templated editing in plants |
| EP4051788A4 (en) | 2019-10-30 | 2023-12-06 | Pairwise Plants Services, Inc. | TYPE V CRISPR CAS BASE EDITORS AND METHODS OF USE THEREOF |
| WO2021092130A1 (en) | 2019-11-05 | 2021-05-14 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| US20230034677A1 (en) | 2019-11-21 | 2023-02-02 | INSERM (Institut National de la Santé et la Recherche (Médicale) | Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines |
| US11976278B2 (en) | 2019-12-06 | 2024-05-07 | Pairwise Plants Services, Inc. | Recruitment methods and compounds, compositions and systems for recruitment |
| CN115380111A (zh) | 2020-01-30 | 2022-11-22 | 成对植物服务股份有限公司 | 用于碱基多样化的组合物、系统和方法 |
| UY39058A (es) | 2020-01-31 | 2021-08-31 | Pairwise Plants Services Inc | Suppresión de la respuesta de evasión a la sombra en plantas |
| WO2021158798A1 (en) | 2020-02-04 | 2021-08-12 | Pairwise Plants Services, Inc. | Thornless / prickleless rubus plants |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2021168288A1 (en) | 2020-02-21 | 2021-08-26 | Pairwise Plants Services, Inc. | Improved resistance to soybean cyst nematode through gene editing |
| US11999946B2 (en) | 2020-03-26 | 2024-06-04 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| US11882808B2 (en) | 2020-03-27 | 2024-01-30 | Pairwise Plants Services, Inc. | Methods for improving resistance to soybean rust |
| WO2021207148A1 (en) | 2020-04-06 | 2021-10-14 | Pairwise Plants Services, Inc. | Methods and compositions for increasing resistance to ear rot and stem rot disease in maize |
| CN119431532A (zh) | 2020-04-16 | 2025-02-14 | 成对植物服务股份有限公司 | 控制分生组织大小以改良作物的方法 |
| MX2022013840A (es) * | 2020-05-04 | 2023-02-09 | Inhibrx Inc | Polipéptidos de unión a pd-1 canina y usos de los mismos. |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| HUE069403T2 (hu) | 2020-05-26 | 2025-03-28 | Boehringer Ingelheim Int | Anti-PD-1 antitestek |
| CN116096230A (zh) | 2020-06-02 | 2023-05-09 | 成对植物服务股份有限公司 | 控制分生组织大小以改良作物的方法 |
| MX2022015896A (es) | 2020-06-17 | 2023-02-22 | Pairwise Plants Services Inc | Métodos para el control del tamaño del meristemo para la mejora de cultivos. |
| EP4172328A1 (en) | 2020-06-30 | 2023-05-03 | Pairwise Plants Services, Inc. | Compositions, systems, and methods for base diversification |
| WO2022047135A1 (en) | 2020-08-28 | 2022-03-03 | Pairwise Plants Services, Inc. | Engineered crispr-cas proteins and methods of use thereof |
| US20220145334A1 (en) | 2020-11-06 | 2022-05-12 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| US20220259612A1 (en) | 2021-02-11 | 2022-08-18 | Pairwise Plants Services, Inc. | Methods and compositions for modifying cytokinin oxidase levels in plants |
| US12365910B2 (en) | 2021-02-25 | 2025-07-22 | Pairwise Plants Services, Inc. | Methods and compositions for modifying root architecture in plants |
| CN113189078B (zh) * | 2021-03-04 | 2024-04-16 | 吉林大学 | 一种靶向药物的高通量筛选方法 |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| US20220403475A1 (en) | 2021-06-14 | 2022-12-22 | Pairwise Plants Services, Inc. | Reporter constructs, compositions comprising the same, and methods of use thereof |
| CN117897050A (zh) | 2021-06-17 | 2024-04-16 | 成对植物服务股份有限公司 | 大豆中生长调节因子家族转录因子的修饰 |
| UY39827A (es) | 2021-06-24 | 2023-01-31 | Pairwise Plants Services Inc | Modificación de genes de ubiquitina ligasa e3 hect para mejorar los rasgos de rendimiento |
| CA3224982A1 (en) | 2021-07-01 | 2023-01-05 | Pairwise Plants Services, Inc. | Methods and compositions for enhancing root system development |
| CN113702351B (zh) * | 2021-07-14 | 2024-08-20 | 吉林大学 | 一种对天然药物产物进行筛选和垂钓的方法 |
| CA3229056A1 (en) | 2021-08-12 | 2023-02-16 | Pairwise Plants Services, Inc. | Modification of brassinosteroid receptor genes to improve yield traits |
| UY39902A (es) | 2021-08-17 | 2023-03-31 | Pairwise Plants Services Inc | Métodos y composiciones para modificar genes de histidina quinasa receptores de citoquinina en plant |
| WO2023034731A1 (en) | 2021-08-30 | 2023-03-09 | Pairwise Plants Services, Inc. | Modification of ubiquitin binding peptidase genes in plants for yield trait improvement |
| AR126938A1 (es) | 2021-09-02 | 2023-11-29 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar la arquitectura de las plantas y los rasgos de rendimiento |
| US20230266293A1 (en) | 2021-09-21 | 2023-08-24 | Pairwise Plants Services, Inc. | Color-based and/or visual methods for identifying the presence of a transgene and compositions and constructs relating to the same |
| EP4405377A1 (en) | 2021-09-21 | 2024-07-31 | Pairwise Plants Services, Inc. | Methods and compositions for reducing pod shatter in canola |
| US20230108968A1 (en) | 2021-10-04 | 2023-04-06 | Pairwise Plants Services, Inc. | Methods for improving floret fertility and seed yield |
| AR127300A1 (es) | 2021-10-07 | 2024-01-10 | Pairwise Plants Services Inc | Métodos para mejorar la fertilidad de la flor y el rendimiento de semillas |
| AR127904A1 (es) | 2021-12-09 | 2024-03-06 | Pairwise Plants Services Inc | Métodos para mejorar la fertilidad de floretes y el rendimiento de semillas |
| WO2023114750A1 (en) | 2021-12-13 | 2023-06-22 | Pairwise Plants Services, Inc. | Model editing systems and methods relating to the same |
| WO2023133440A1 (en) | 2022-01-06 | 2023-07-13 | Pairwise Plants Services, Inc. | Methods and compositions for trichome removal |
| KR20240137086A (ko) | 2022-01-28 | 2024-09-19 | 조지아뮨 인코포레이티드 | Pd-1 작용제인 세포예정사 단백질 1에 대한 항체 |
| AR128372A1 (es) | 2022-01-31 | 2024-04-24 | Pairwise Plants Services Inc | Supresión de la respuesta de evitación de la sombra en las plantas |
| CA3253290A1 (en) | 2022-02-28 | 2023-08-31 | Pairwise Plants Services, Inc. | MODIFIED CRISPR-CAS EFFECTOR PROTEINS AND THEIR METHODS OF USE |
| CN119072487A (zh) | 2022-03-02 | 2024-12-03 | 成对植物服务股份有限公司 | 用于改善产量性状的油菜素类固醇受体基因的修饰 |
| CN115015536A (zh) * | 2022-03-30 | 2022-09-06 | 邹灵龙 | 一种即时检测pd-1抗体药浓度的试纸条和试剂盒 |
| EP4499842A1 (en) | 2022-03-31 | 2025-02-05 | Pairwise Plants Services, Inc. | Early flowering rosaceae plants with improved characteristics |
| US20230357789A1 (en) | 2022-04-07 | 2023-11-09 | Pairwise Plants Services, Inc. | Methods and compositions for improving resistance to fusarium head blight |
| CN119278208A (zh) | 2022-04-21 | 2025-01-07 | 成对植物服务股份有限公司 | 用于改善产量性状的方法和组合物 |
| EP4519428A1 (en) | 2022-05-02 | 2025-03-12 | Pairwise Plants Services, Inc. | Methods and compositions for enhancing yield and disease resistance |
| CA3250542A1 (en) | 2022-05-05 | 2023-11-09 | Pairwise Plants Services, Inc. | METHODS AND COMPOSITIONS FOR MODIFYING ROOT ARCHITECTURE OR IMPROVING PLANT YIELD PROPERTIES |
| UY40326A (es) | 2022-06-27 | 2023-12-29 | Pairwise Plants Services Inc | Métodos y composiciones para modificar el escape a la sombra en plantas |
| AR129749A1 (es) | 2022-06-29 | 2024-09-25 | Pairwise Plants Services Inc | Métodos y composiciones para controlar el tamaño del meristemo para el mejoramiento de cultivos |
| WO2024006792A1 (en) | 2022-06-29 | 2024-01-04 | Pairwise Plants Services, Inc. | Methods and compositions for controlling meristem size for crop improvement |
| WO2024030984A1 (en) | 2022-08-04 | 2024-02-08 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield traits |
| CA3264244A1 (en) | 2022-08-11 | 2024-02-15 | Pairwise Plants Services, Inc. | METHODS AND COMPOSITIONS FOR REGULATING MERISTEME SIZE FOR CROP IMPROVEMENT |
| EP4584282A1 (en) | 2022-09-08 | 2025-07-16 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield characteristics in plants |
| CN120500534A (zh) | 2022-12-16 | 2025-08-15 | 成对植物服务股份有限公司 | 包含Cas12a多肽和内含肽的融合蛋白和其使用方法 |
| AU2023413056A1 (en) | 2022-12-21 | 2025-06-12 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| US20240279673A1 (en) | 2023-02-16 | 2024-08-22 | Pairwise Plants Services, Inc. | Methods and compositions for modifying shade avoidance in plants |
| CN120897995A (zh) | 2023-03-01 | 2025-11-04 | 成对植物服务股份有限公司 | 经工程化的蛋白质和其使用方法 |
| AR132019A1 (es) | 2023-03-02 | 2025-05-21 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la evitación de la sombra en plantas |
| AR132071A1 (es) | 2023-03-09 | 2025-05-21 | Pairwise Plants Services Inc | Modificación de genes de la vía de señalización de brasinoesteroide para mejorar rasgos de rendimiento en plantas |
| WO2024206375A1 (en) | 2023-03-30 | 2024-10-03 | Pairwise Plants Services, Inc. | Methods and compositions for reducing thorns or prickles in plants |
| WO2024216028A1 (en) | 2023-04-12 | 2024-10-17 | Agenus Inc. | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor |
| AU2024269008A1 (en) | 2023-05-10 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| UY40746A (es) | 2023-05-18 | 2024-12-13 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar las características de rendimiento de las plantas |
| AR133164A1 (es) | 2023-07-18 | 2025-09-03 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la arquitectura radicular en plantas |
| AR133310A1 (es) | 2023-07-27 | 2025-09-17 | Pairwise Plants Services Inc | Métodos y composiciones para modificar rasgos de rendimiento de las plantas |
| WO2025064734A1 (en) | 2023-09-21 | 2025-03-27 | Pairwise Plants Services, Inc. | Early flowering black raspberry plants with improved characteristics |
| WO2025072430A1 (en) | 2023-09-26 | 2025-04-03 | Pairwise Plants Services, Inc. | Crispr-cas fusion proteins with adenine base editor functionality, compositions comprising the same, and methods of use thereof |
| US20250129348A1 (en) | 2023-10-09 | 2025-04-24 | Pairwise Plants Services, Inc. | Circular permutants, compositions comprising the same, and methods of use thereof |
| WO2025080600A1 (en) | 2023-10-11 | 2025-04-17 | Pairwise Plants Services, Inc. | Methods and compositions for improving crop yield traits |
| US20250207154A1 (en) | 2023-12-21 | 2025-06-26 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| US20250270578A1 (en) | 2024-02-22 | 2025-08-28 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield characteristics in plants |
| WO2025252855A1 (en) | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta |
| WO2025252857A1 (en) | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | Il-15 muteins with ph-dependent binding for il-15ralpha |
| US12428636B1 (en) | 2024-07-08 | 2025-09-30 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| JP3011939B2 (ja) | 1987-03-02 | 2000-02-21 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 組換えミコバクテリア・ワクチン |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
| WO1991013157A1 (en) | 1990-02-26 | 1991-09-05 | Commonwealth Scientific And Industrial Research Organisation | Shuttle plasmid for escherichia coli and mycobacteria |
| GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2110682A1 (en) | 1991-06-06 | 1992-12-10 | Charles K. Stover | Induction of ctl responses to foreign antigens expressed in mycobacteria |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| JP3454275B2 (ja) | 1992-06-05 | 2003-10-06 | 佑 本庶 | プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ |
| AU7203194A (en) | 1993-06-04 | 1995-01-03 | New York University | Bispecific human monoclonal antibodies specific for human immunodeficiency virus |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| EP1445264B1 (en) | 2001-07-31 | 2011-09-14 | Ono Pharmaceutical Co., Ltd. | Substance specific to pd-1 |
| EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
| BR0316880A (pt) * | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| ATE500345T1 (de) | 2003-01-07 | 2011-03-15 | Dyax Corp | Kunitz-domäne-bibliothek |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| MX351401B (es) | 2005-06-08 | 2017-10-13 | Dana Farber Cancer Inst Inc | Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1). |
| NZ594510A (en) | 2006-12-27 | 2012-06-29 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| TW201007669A (en) | 2008-08-01 | 2010-02-16 | Integrated Solutions Technology Inc | A display driving device and the driving method thereof |
| AU2009290543B2 (en) * | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| WO2011110604A1 (en) * | 2010-03-11 | 2011-09-15 | Ucb Pharma, S.A. | Pd-1 antibody |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| WO2012062218A1 (en) | 2010-11-11 | 2012-05-18 | The University Of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| PL2691112T3 (pl) | 2011-03-31 | 2018-09-28 | Merck Sharp & Dohme Corp. | Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| US9090994B2 (en) | 2011-06-08 | 2015-07-28 | Nanjingjinsirui Science & Technology Biology Corp. | Antibody humanization by framework assembly |
| TW202114735A (zh) * | 2011-08-01 | 2021-04-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| AU2013201121A1 (en) | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| EP2817619B1 (en) * | 2012-02-23 | 2018-07-25 | Sloan Kettering Institute For Cancer Research | Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| DK2904011T3 (en) * | 2012-10-02 | 2017-12-04 | Bristol Myers Squibb Co | COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATMENT OF CANCER |
| CN105339389B (zh) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| ES2927567T3 (es) * | 2013-09-13 | 2022-11-08 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| EP3177644B1 (en) * | 2014-08-05 | 2020-10-07 | Mabquest SA | Immunological reagents binding to pd-1 |
| WO2016106159A1 (en) | 2014-12-22 | 2016-06-30 | Enumeral Biomedical Holding, Inc. | Anti-pd-1 antibodies |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| EP3405497A2 (en) * | 2016-01-22 | 2018-11-28 | Mabquest SA | Immunological reagents |
-
2015
- 2015-08-05 EP EP15750136.2A patent/EP3177644B1/en active Active
- 2015-08-05 US US15/329,760 patent/US9982053B2/en active Active
- 2015-08-05 CA CA2957258A patent/CA2957258C/en active Active
- 2015-08-05 WO PCT/IB2015/055943 patent/WO2016020856A2/en not_active Ceased
- 2015-08-05 ES ES15750136T patent/ES2847311T3/es active Active
- 2015-08-05 PT PT157501362T patent/PT3177644T/pt unknown
- 2015-08-05 DK DK15750136.2T patent/DK3177644T3/da active
- 2015-08-05 CN CN201580042199.7A patent/CN107074947B/zh active Active
- 2015-08-05 AU AU2015298356A patent/AU2015298356B2/en active Active
- 2015-08-05 JP JP2017526774A patent/JP6629321B2/ja active Active
- 2015-08-05 PL PL15750136T patent/PL3177644T3/pl unknown
- 2015-08-05 SG SG11201700672YA patent/SG11201700672YA/en unknown
- 2015-08-05 KR KR1020177004575A patent/KR102357893B1/ko active Active
-
2018
- 2018-05-17 US US15/981,977 patent/US11130807B2/en active Active
-
2021
- 2021-09-27 US US17/485,752 patent/US20220169733A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531028A5 (enExample) | ||
| RU2008146922A (ru) | Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk) | |
| JP2018532766A5 (enExample) | ||
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2017519759A5 (enExample) | ||
| JP2020097579A (ja) | 毒性部分を備える異常細胞拘束性免疫グロブリン | |
| JP2013506428A5 (enExample) | ||
| US9856319B2 (en) | Monovalent binding proteins | |
| JP2019500020A5 (enExample) | ||
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| JP2016503295A5 (enExample) | ||
| JP2020515247A5 (enExample) | ||
| JP2007526880A5 (enExample) | ||
| BR112013001640A2 (pt) | anticorpo monoclonal que se liga aos epítopos de epha2 e cd44, seu uso no tratamento de câncer e na detecção de célula cancerosa, bem como composição, kit, ácido nucleico e vetor 5 de expressão | |
| JP2015519375A5 (enExample) | ||
| JP2020534012A5 (enExample) | ||
| JP2020500834A5 (enExample) | ||
| JP2020515277A5 (enExample) | ||
| Aria et al. | Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: a systematic review | |
| WO2023131193A1 (zh) | 靶向人b7-h3分子的人源化单克隆抗体及其应用 | |
| CN119948063A (zh) | 结合egfr和b7-h3的双特异性抗体 | |
| JP7711208B2 (ja) | Ｄｌｌ３に対する結合分子及びその使用 | |
| JP2019509046A5 (enExample) | ||
| KR101828794B1 (ko) | 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 항체 | |
| US20230365676A1 (en) | Cd33 antibodies |